ZeroEyes Launches Pilot Program with Modesto Police Department to Enhance Public Safety
Northern California PD Deploys Proactive AI Gun Detection Technology to Reduce Crime and Improve Police Response Times
ZeroEyes, the creators of the only AI-based gun detection video analytics platform that holds the full U.S. Department of Homeland Security SAFETY Act Designation, today announced that its proactive gun detection and intelligent situational awareness platform has been deployed by the Modesto Police Department (PD) in strategic locations throughout the city. This partnership reflects the Modesto Police Department's commitment to utilizing the latest tools to improve public safety and reduce crime in the community.
'We want our community members to feel secure in their work, leisure, and daily lives,' said Cat McFadon, Police Civilian Manager of Modesto PD. 'ZeroEyes' ability to detect firearms and trigger instant alerts will allow us to respond more quickly and efficiently to gun-related threats. With this additional technology in our toolbelt, we're reinforcing our efforts to drive down crime and make Modesto a safer place for everyone.'
Modesto, a city of 216,000 residents in Northern California, is known for its progressive law enforcement efforts. The department has a long-standing dedication to equipping its officers with the most advanced technology to support their mission to protect life and property. This pilot program is intended to assess the effectiveness of ZeroEyes technology in real-world conditions, with the goal of expanding its use in key areas such as local schools and the city's shopping mall.
ZeroEyes' AI gun detection and intelligent situational awareness software layers onto existing digital security cameras. If a gun is identified, images are instantly shared with the ZeroEyes Operations Center (ZOC), the industry's only U.S.-based, fully in-house operation center, which is staffed 24/7/365 by specially trained military and law enforcement veterans. If these experts determine that the threat is valid, they dispatch alerts and actionable intelligence — including visual description, gun type, and last known location — to Modesto PD as quickly as 3 to 5 seconds from detection.
'The Modesto PD's commitment to increasing public safety through innovative technology aligns perfectly with our mission, and we look forward to the collaboration,' said Mike Lahiff, CEO of ZeroEyes. 'We're confident that ZeroEyes will not only meet but exceed Modesto PD's expectations, enhancing response times and reducing the impact of gun-related threats.'
About ZeroEyes
ZeroEyes delivers a proactive, human-verified AI gun detection software solution that integrates into existing digital security cameras and helps to mitigate mass shootings and gun-related violence by reducing response times, providing actionable intelligence with images, and delivering clarity among chaos — ultimately saving lives. ZeroEyes' patented solution has been recognized by the U.S. Department of Homeland Security (DHS) as a promising anti-terrorism technology and is the first video analytics technology to receive full SAFETY Act DT&E Designation.
Founded by Navy SEALs and elite technologists, ZeroEyes dispatches accurate and real-time actionable intelligence about the illegal brandishing of a gun near or in an occupied area or building, to local staff and law enforcement with an image of the shooter(s) and location of the threat, as quickly as 3 to 5 seconds from the moment the gun is detected.
The ZeroEyes team also provides tech consulting, installation assistance and practice drills for active shooter events to enhance safety at schools, corporate and government facilities. Headquartered in the Greater Philadelphia area, the company's affordable and effective gun detection solution has been adopted by the US Department of Defense, leading public K-12 school districts, colleges/universities, healthcare facilities, commercial property groups, manufacturing plants, Fortune 500 corporate campuses, shopping malls, big-box retail stores and more. Learn more about ZeroEyes at ZeroEyes.co m.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
2 hours ago
- New York Post
Simple tool could detect Parkinson's disease early — it was 96% accurate in experiments
This pen truly is mightier than the sword. A team of researchers at UCLA has developed a high-tech diagnostic pen that can detect signs of Parkinson's disease with over 96% accuracy, offering a low-cost way to identify the neurodegenerative disorder far earlier than now. A pilot study in the journal Nature Chemical Engineering unveiled the device, which looks much like a regular pen. 3 A patient with PD using the diagnostic pen for a writing task. Nature Chemical Engineering It's able pick up on subtle motor dysfunctions before they're visible to the naked eye, all by analyzing how people write. So, how does this futuristic fountain pen work? The tip is made of a flexible silicone material infused with magnetic particles, and it writes using a special ferrofluid ink that contains nanomagnets. As someone writes, pressure from the hand deforms the tip, causing changes in magnetic fields that produce electrical signals — like a Morse code of motor function. Those signals are then analyzed to detect the difference between healthy and Parkinson's-affected motor patterns. In tests with 16 participants — including 3 with Parkinson's — the system nailed the diagnosis with 96.22% accuracy. Even more impressive? The pen worked whether people wrote on paper or in the air, meaning it doesn't even require a surface. 3 Nature Chemical Engineering Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. This diagnostic pen is portable, inexpensive and doesn't rely on a neurologist to interpret results, making it a promising option for remote screenings, home use or even telehealth checkups. 'Our development of the diagnostic pen represents a low-cost, widely disseminable and reliable technology with the potential to improve PD diagnostics across large populations and resource-limited areas,' the researchers wrote. With further validation in a larger population, the device could be used not just for early diagnosis, but for ongoing symptom tracking and personalized treatment monitoring. 3 Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. highwaystarz – This is just the latest innovation aimed at tackling Parkinson's disease, which affects more than 10 million people worldwide and has no known cure. A recent study found that psilocybin — the psychedelic compound that gave 'magic mushrooms' their trippy reputation in the 1960s — showed serious promise for improving mood and motor function in people with Parkinson's disease. Tavapadon — a new drug that mimics dopamine by targeting certain receptors — has also shown promise in clinical trials by reducing motor fluctuations and maintaining symptom control with fewer side effects than traditional therapies. Produodopa — a continuous infusion therapy first administered in the UK — was approved by the US Food and Drug Administration last fall. Innovative approaches targeting the psychological aspects of the disease have been successful as well — with tandem cycling proving to be especially popular. Some New Yorkers even find relief by playing pingpong.
Yahoo
5 days ago
- Yahoo
Sanofi announces new data from two clinical studies on Sarclisa
New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously via an on-body injector in relapsed or refractory multiple myeloma support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa's efficacy and safety profile. The results were presented at the American Society of Clinical Oncology Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous infusion. The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection. The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections' enFuse hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa. The enFuse device uses a 30 gauge, hidden, and retractable needle that is smaller compared to some of the commonly used large-volume SC injection needles, which may support patient comfort. The safety and efficacy of Sarclisa SC administered with the OBI or manual administration are investigational and have not been approved for use by any regulatory authority. IRAKLIA is a global, randomized, open-label, pivotal phase 3 non-inferiority study comparing Sarclisa SC administered via an OBI and Sarclisa IV, both in combination with pomalidomide and dexamethasone in adult patients with R/R MM who have received at least one prior line of treatment. At the data cut-off of November 6, 2024, and a median follow-up of 12 months, the study demonstrated: Primary endpoints: Objective response rate with Sarclisa SC-Pd was 71.1% compared to 70.5% with Sarclisa IV-Pd, establishing non-inferiority. Observed Sarclisa mean concentration before dosing at steady state with Sarclisa SC-Pd was 499 ug/mL compared to 341 ug/mL with Sarclisa IV-Pd, establishing non-inferiority. Secondary endpoints Very good partial response or better rates were consistent between Sarclisa SC-Pd and Sarclisa IV-Pd at 46.4% and 45.9%, respectively. Observed Sarclisa mean C trough at 4 weeks with Sarclisa SC-Pd was 421 ug/mL compared to 302 ug/mL with Sarclisa IV-Pd. Systemic infusion reactions were significantly lower with Sarclisa SC-Pd, occurring in only 1.5% of patients compared to 25% of those treated with Sarclisa IV-Pd. Of note, nearly all IRs occurring were grade 1 or 2 and resolved within one day. No patients in the Sarclisa SC-Pd arm discontinued treatment due to a systemic IR. Most Sarclisa SC-Pd-treated patients reported being satisfied or very satisfied with their injection compared to 53.4% in the Sarclisa IV-Pd arm, demonstrating the positive impact of this innovative method of administration on the patient experience. 99.9% of Sarclisa SC OBI injections were successfully delivered with no significant safety concerns related to the OBI. Progression-free survival rates at 12 months were also similar, reaching 66.1% for patients treated with Sarclisa SC-Pd compared to 65.1% of patients treated with Sarclisa IV-Pd. The overall safety profile of Sarclisa SC-Pd observed in this study was consistent with the established safety profile of Sarclisa IV-Pd, but with a notably lower rate of systemic IRs. No new safety concerns were observed, except for low-grade local injection site reactions associated with SC administration that occurred with a low incidence. Nearly all ISRs were grade 1, except for one episode of grade 2. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on SNY: Disclaimer & DisclosureReport an Issue Sanofi price target raised to EUR 110 from EUR 108 at Guggenheim Sanofi price target lowered to EUR 118 from EUR 120 at Berenberg Oppenheimer bullish on Nurix as Sanofi opt-in, competitor data derisk STAT6 Sanofi price target lowered to EUR 108 from EUR 121 at Guggenheim Morning Movers: Trump to bump steel tariffs, pharma companies announce deals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Yahoo
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal
On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for treatment-resistant depression (TRD), generally defined as a failure on two or more antidepressants. Alto paid Chase Therapeutics an upfront payment of $1.75 million. Chase Therapeutics will be eligible for up to $71.5 million in milestone payments, $41 million of the potential future milestone payments are tied to the product candidates' commercial success. Alto expects its current cash balance to support planned operations into 2028 through five clinical trial readouts across its pipeline most advanced program, ALTO-207 (formerly known as CTC-501), is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist, approved for Parkinson's disease with demonstrated antidepressant effect, and ondansetron, an antiemetic, selective 5-HT3 receptor antagonist. As a fixed-dose combination, ALTO-207 enables rapid titration and higher dosing by mitigating the dose-limiting adverse events typically experienced with pramipexole. Phase 2a trial of CTC-501 Chase Therapeutics completed a Phase 2a trial evaluating CTC-501 in 32 patients with depression. The primary endpoint was achieved in the study. Patients randomized to receive CTC-501 reached a mean dose of 4.1mg per day, with 67% achieving the highest allowable dose of 5mg/day. CTC-501 was generally well tolerated in the maintenance period of the study. CTC-501 demonstrated statistically significant and clinically meaningful improvements from baseline compared to placebo on depression symptoms as measured by the Montgomery Åsberg Depression Rating Scale or MADRS. CTC-501 also demonstrated significantly greater improvement on the Clinician Global Impression Scale of Severity (CGI-S) compared to placebo. Alto expects to initiate a Phase 2b trial, designed to be a potentially pivotal study, with ALTO-207 in patients with TRD by mid-2026 and report topline data in 2027. Phase 2a Trial For CTC-413 ALTO-208 (or CTC-413) is a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist. ALTO-208 is being developed for patients with Parkinson's disease (PD). Chase Therapeutics completed a blinded Phase 2a trial evaluating CTC-413 in 13 patients with PD. The mean tolerated dose of CTC-413 significantly exceeded pramipexole. Six subjects (67%) tolerated CTC-413 at the maximum dose of 9.0mg/day, and all but one remained on that dose throughout the final three-month treatment period. CTC-413 demonstrated favorable safety and tolerability with no unexpected, serious or persistent issues. William Blair reiterated an Outperform rating on Alto Neuroscience, viewing the acquisition of ALTO-207 as an 'intriguing asset.' The firm noted the impressive efficacy of pramipexole in the PAX-D study but also highlighted the possibility of functional unblinding in that study, which may have contributed to the perceived efficacy. Price Action: ANRO stock is trading higher by 2.31% to $2.66 at last check Tuesday Read Next:Photo by fizkes via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
